180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters
25 mars 2021 08h30 HE
|
180 Life Sciences Corp.
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
15 mars 2021 11h12 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
24 févr. 2021 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
09 févr. 2021 08h00 HE
|
Equillium
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
02 févr. 2021 14h05 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
New book provides a simple solution to conquer inflammation, the underlying cause of the majority of the disease today
18 janv. 2021 18h00 HE
|
Balboa Press
SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- As a cancer survivor who has experienced the devastating effects of cancer, Dr. Bruce Howe made it his mission to research the subject of inflammation...
Specialized Pro-Resolving Mediators (SPMs) Shown to Resolve Inflammation and Improve Infection Clearance
13 janv. 2021 10h15 HE
|
Life Extension
Fort Lauderdale, FL, Jan. 13, 2021 (GLOBE NEWSWIRE) -- A recent review article describes how compounds called specialized pro-resolving mediators (SPMs) may be a viable treatment for inflammatory...
Juva Life Introduces Advisory Team in Preparation for Advancement Towards “Precision Cannabis”
08 déc. 2020 04h30 HE
|
Juva Life Inc.
VANCOUVER, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based...
US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc.
24 nov. 2020 16h58 HE
|
US Capital Global
San Francisco, California, Nov. 24, 2020 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, is offering to eligible investors an investment opportunity of up to...
Enosi Life Sciences Files Patent for TNF-Inhibiting Molecules EN1001, EN2001 and EN3001
18 nov. 2020 09h00 HE
|
Enosi Life Sciences
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for...